Somewhat Favorable News Coverage Somewhat Unlikely to Affect Benitec Biopharma (BNTC) Stock Price
Media headlines about Benitec Biopharma (NASDAQ:BNTC) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Benitec Biopharma earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.9561288705451 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of brokerages have recently issued reports on BNTC. ValuEngine raised shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Maxim Group reissued a “hold” rating on shares of Benitec Biopharma in a report on Wednesday, August 30th.
Shares of Benitec Biopharma (BNTC) traded down $0.01 during trading on Wednesday, hitting $2.95. 16,100 shares of the stock were exchanged, compared to its average volume of 281,961. Benitec Biopharma has a 52-week low of $1.36 and a 52-week high of $5.48.
Benitec Biopharma Company Profile
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.